Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 900 of 3499 entries
View as:

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03701282 Org: User:
Start: 02/12/19 End: 05/07/28 Due: 05/07/29

Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00365391 Org: User:
Start: 08/31/06 End: 06/30/10 Due: 06/30/11

Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00828984 Org: User:
Start: 10/31/09 End: 10/31/14 Due: 10/31/15

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01950390 Org: User:
Start: 01/24/14 End: 01/31/26 Due: 01/31/27

AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00659360 Org: User:
Start: 02/29/08 End: 11/30/12 Due: 11/30/13

A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT00001438 Org: User:
Start: 06/30/95 End: 12/31/00 Due: 12/31/01

Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01623869 Org: User:
Start: 07/31/12 End: 02/28/15 Due: 02/28/16

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01196416 Org: User:
Start: 08/31/10 End: 08/31/15 Due: 08/31/16

Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00025246 Org: User:
Start: 09/30/01 End: - Due: -

Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00023959 Org: User:
Start: 07/31/01 End: - Due: -

Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

Phase: N/A Priority: Normal
NCT ID: NCT05198843 Org: User:
Start: 11/08/22 End: 12/20/23 Due: 12/20/24

Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments

Phase: N/A Priority: Normal
NCT ID: NCT01445314 Org: User:
Start: 03/23/07 End: 08/08/24 Due: 08/08/25

Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction

Phase: N/A Priority: Normal
NCT ID: NCT00062374 Org: User:
Start: 06/30/03 End: 06/30/11 Due: 06/30/12

Collection of Blood From Patients With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00034216 Org: User:
Start: 07/16/02 End: - Due: -

Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00096278 Org: User:
Start: 09/15/04 End: 12/31/12 Due: 12/31/13

S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00617708 Org: User:
Start: 03/31/08 End: 02/25/14 Due: 02/25/15

LMB-2 to Treat Hairy Cell Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00321555 Org: User:
Start: 05/02/06 End: 12/31/22 Due: 12/31/23

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02203526 Org: User:
Start: 08/14/14 End: 06/15/27 Due: 06/15/28

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01727076 Org: User:
Start: 02/15/13 End: 06/30/16 Due: 06/30/17

RO4929097 in Treating Patients With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01116687 Org: User:
Start: 05/31/10 End: 03/31/12 Due: 03/31/13

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01369849 Org: User:
Start: 09/30/11 End: 02/28/14 Due: 02/28/15

Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00077376 Org: User:
Start: 03/31/05 End: 03/31/11 Due: 03/31/12

Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00022971 Org: User:
Start: 08/15/01 End: 03/17/17 Due: 03/17/18

Phase I Study of Intrathecal Mafosfamide

Phase: N/A Priority: Normal
NCT ID: NCT00001251 Org: User:
Start: 11/30/89 End: 11/30/03 Due: 11/30/04

Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00243100 Org: User:
Start: 11/30/05 End: - Due: -